Triangulation Or The Bermuda Triangle: Can Trump Work With House Dems On Drug Prices?
Executive Summary
President Trump is highlighting drug pricing as an area where he may be able to work with the new Democratic majority in the House. The political wisdom of building common ground on the topic is hard to ignore – but the tempestuous personality of the President is still the overriding factor. Instead, focus on whether HHS can win some breathing room to keep going with administrative changes.
You may also be interested in...
A Big Day For Drug Pricing: Senate Hearing Will Overlap With House Committee’s
Senate Finance Committee's Jan. 29 witnesses will include economists, a patient advocate and “others,” to be announced in the coming days, panel says.
DTC Ad Proposal: Biopharma, Advertisers Marshall Legal Arguments In Opposition
Industry comments urge CMS to withdraw proposed rule mandating list price disclosures in TV ads, citing legal conflicts.
Drug Pricing In The Next Senate: Incoming Finance Chair Grassley Outlines Priorities
A key figure in determining what Rx bills advance in Congress, Grassley recently expressed interest in working with House Democrats in a floor speech on his drug pricing priorities.